“Most founders dominate organisations, spending 70-hour weeks trying to control everything. But it’s not about the hours you work – it’s about the impact. That shift in mindset transformed how I built multiple successful businesses in pharma services,” explains Raman
Frontier Scientific Solutions is leveraging its Free Trade Zone (FTZ) at Wilmington International Airport (ILM) to help life sciences companies mitigate supply chain disruptions and cost increases as new U.S. trade tariffs take effect. The FTZ designation offers tariff deferrals, exemptions,
Genprex, Inc., a clinical-stage gene therapy company, has announced a strategic collaboration with a contract development and manufacturing organisation (CDMO) to explore a second-generation approach for delivering its diabetes gene therapy drug candidate. The research will focus on using a
C3i has obtained regulatory approval from the European Medicines Agency (EMA) to manufacture cell therapies for the European market. The certification follows an inspection of the company’s Montreal facility, which confirmed compliance with Good Manufacturing Practice (GMP) standards. This approval enables C3i, a Canadian contract development and
Brexogen, a biotechnology company specialising in exosome-based therapeutics, has signed a licensing and technology transfer agreement with BMI Korea for BxC-I17e. The agreement represents the first major licensing deal for an exosome therapeutic in Korea and marks a key milestone in the
Biogen Inc. and Stoke Therapeutics, Inc. have entered into a collaboration to develop and commercialize zorevunersen, an investigational treatment for Dravet syndrome, in all territories outside the U.S., Canada, and Mexico. The agreement grants Biogen exclusive commercialization rights outside these regions,
Celonic Group has entered a multi-year commercial manufacturing agreement with LINDIS Biotech to produce catumaxomab, a bispecific monoclonal antibody designed for the treatment of malignant ascites in patients with EpCAM-positive carcinomas. The agreement strengthens Celonic’s role as a CDMO in biologics contract manufacturing. Catumaxomab is a first-in-class therapy
Indena has become the first active pharmaceutical ingredient (API) manufacturer worldwide to obtain a European Pharmacopoeia Certificate of Eligibility (CEP) for its cannabidiol (CBD) extract. Issued by the European Directorate for the Quality of Medicines (EDQM), the certification confirms that Indena’s
Merck KGaA has appointed three new members to its Executive Board, marking a significant leadership transition as part of the company’s long-term growth strategy. Jean-Charles Wirth, Danny Bar-Zohar, and Khadija Ben Hammada will assume their new roles in 2025, ensuring continuity
Andelyn Biosciences, Inc., a cell and gene therapy CDMO, has expanded its AAV Curator Platform and License Agreement with the Broad Institute of MIT and Harvard. The agreement now includes the Stanton Lab CNS capsids, which enhance brain transduction while
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
